Transcriptomics Market Analysis

The market is divided by technology into microarray, real-time PCR, sequencing technology, and others out of which, the real-time PCR segment is anticipated to hold a substantial share in the global transcriptomics market over the forecast period on account of growing use of polymerase chain reaction (PCR) to study the genetic sample.

Based on end-user, the market is segmented into clinical research centers, hospitals, specialty clinics, and others, out of which, the clinical research centers segment is anticipated to gain notable share in terms of revenue during the forecast period, on the back of increasing investment in the medical research and development activities. According to the World Bank data, 2.204% of the global GDP was spent for R&D activities in 2018.

Our in-depth analysis of the global market includes the following segments:

By Technology

Microarray
Real-time PCR
Sequencing Technology
Others

By Application

Clinical Diagnostics
Drug Discovery
Others

By End-User

Clinical Research Centers
Hospitals
Specialty Clinics
Others

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of transcriptomics is estimated at USD 7.45 billion.

Transcriptomics Market size was valued at USD 7.04 billion in 2023 and is poised to cross USD 17.59 billion by 2036, expanding at more than 7.3% CAGR during the forecast period i.e., between 2024-2036. Increasing personalized approach towards treatment of rare diseases will boost the market growth.

Asia Pacific industry is likely to hold largest revenue share by 2036, on the back of rising healthcare expenditure across the region.

The major players in the market are Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., CD Genomics, F. Hoffmann-La Roche AG, GenXPro GmbH, Qiagen N.V., Illumina, Inc., The Merck Group, Siemens AG, and others.

Transcriptomics Market Analysis